温馨提示：本站仅提供公开网络链接索引服务，不存储、不篡改任何第三方内容，所有内容版权归原作者所有
AI智能索引来源：http://www.pr.com/press-release/907326
点击访问原文链接

Biomed Industries to Present Groundbreaking Research at AD/PD™ 2024 International Conference - PR.com

进入原网站 导航首页
Biomed Industries to Present Groundbreaking Research at AD/PD™ 2024 International Conference - PR.com Join Now Sign In Businesses Business Directory Products & Services Post Your Profile Press Releases Press Release Pricing Submit Press Release Press Release Distribution Recent Press Releases Become a Publishing Partner For Journalists Press Releases Businesses Products & Services Products Services Press Releases Submit Press Release ✕ Press Releases Press Release Pricing Submit Press Release Press Release Distribution Recent News Recent News News by Category News by US Region News by Country RSS News Feeds Business News Lifestyle News Public Interest News Technology News Become a Publishing Partner For Journalists Businesses Business Directory Products & Services Post Your Profile Join Now Sign In Press Release Pricing Recent News Business Lifestyle Public Interest Technology Press Release Pricing Create Account Press Release Pricing Submit Press Release Press Release Distribution Recent News Recent News News by Category News by US Region News by Country Become a Publishing Partner For Journalists RSS News Feeds Business News Lifestyle News Public Interest News Technology News Press Releases>Medical & Health>Biomed Industries Inc.> Biomed Industries Inc. Biomed Industries Inc. Press Releases More Biomed Industries to Present Groundbreaking Research at AD/PD™ 2024 International Conference Get Email Alert RSS San Jose, CA, March 06, 2024 --(PR.com)-- Biomed Industries, Inc. (Biomed), a leading bio-pharmaceutical company, is set to present three significant papers at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases, taking place in Lisbon, Portugal, from March 5 to 9.

The presentations by Biomed include:
· Neurogenesis and Clinical Trials Of NA-831 for Alzheimer's Disease and Major Depressive Disorder

· A Phase 3 Clinical Protocol to Study the Safety and Efficacy Of NA-831 in Combination with Lecanemab In Subjects with Early Alzheimer's Disease

· What does Amyloid-Beta (Aβ) have to do with Alzheimer's Disease? A History of Failure

AD/PD™ 2024 attracts leading medical and scientific professionals worldwide and serves as a pivotal platform for disseminating cutting-edge research on Alzheimer’s, Parkinson’s, and related neurodegenerative diseases. The conference, renowned for its exploration of disease mechanisms and advancements in treatment, emphasizes prevention and therapy strategies across various neurodegenerative conditions.

“We are excited to present our research on Neurogenesis as a rapidly emerging alternative to current therapeutic approaches in Alzheimer’s Disease. Both the safety and efficacy of NA-831 in our Phase 2 clinical trial has shown results that far exceed the recently FDA approved drugs for AD.” said Lloyd Tran, Founder and CEO of Biomed Industries. He continued: “As it has become increasingly clear that new approaches are needed, we stand at the forefront of this new frontier.”

Biomed is soon to conduct a Phase 2B Alzheimer’s Disease (AD) trial and a Phase 3 trial of NA-831 for Major Depressive Disorder (MDD), with plan seek FDA approval of NA-831 for treatment of both AD and MDD.

About Biomed Industries, Inc.:

Biomed Industries, Inc. is a pioneering bio-pharmaceutical company dedicated to developing and commercializing novel drug therapeutics to address unmet medical needs. The company's research team has developed a new platform of drugs targeting Alzheimer’s disease, Major Depressive Disorder (MDD), Diabetes Obesity, and rare diseases, including Rett Syndrome and Fragile X.

For further information, please visit Biomed Industries' official website: https://www.biomedind.com Contact Biomed Industries, Inc.
Michael Willis
800-824-5135
www.biomedind.com Contact Categories Medical & Health PR.com Press Release Distribution Submit Press Release Press Release Pricing Press Release Distribution Account Create Free Account Post Your Profile Resources Recent News RSS News Feeds For Journalists Articles Company About Contact Become a Publishing Partner Terms Privacy © 2026 PR.com and its licensors Terms Privacy Follow PR.com

智能索引记录